{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:27:37Z","timestamp":1792783657360,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NIH","award":["RO1 AI11657503"],"award-info":[{"award-number":["RO1 AI11657503"]}]}],"content-domain":{"domain":["ajpm-online.net","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Preventive Medicine"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.amepre.2019.10.022","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:26:18Z","timestamp":1580171178000},"page":"487-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pneumococcal Vaccination in Adults Aged \u226565 Years: Cost-Effectiveness and Health Impact in U.S. Populations"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4541-0161","authenticated-orcid":false,"given":"Angela R.","family":"Wateska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Patricia","family":"Nowalk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chyongchiou J.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee H.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Schaffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.amepre.2019.10.022_bib0001","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.amepre.2019.10.022_bib0002","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.amepre.2019.10.022_bib0003","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s11606-016-3651-0","article-title":"Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States","volume":"31","author":"Stoecker","year":"2016","journal-title":"J Gen Intern Med"},{"issue":"37","key":"10.1016\/j.amepre.2019.10.022_bib0004","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.amepre.2019.10.022_bib0005","unstructured":"Matanock A. Considerations for PCV13 use among adults >65 years old and a summary of the evidence to recommendations framework. Advisory Committee on Immunization Practices, June 2019 Meeting.www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2019-06\/Pneumococcal-2-Matanock-508.pdf. Updated August 29, 2019. Accessed November 5, 2019."},{"issue":"8","key":"10.1016\/j.amepre.2019.10.022_bib0006","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1001\/jama.2012.169","article-title":"Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine","volume":"307","author":"Smith","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2019.10.022_bib0007","series-title":"Impact of PCV13 on Invasive Pneumococcal Disease (IPD) Burden and the Serotype Distribution in the U.S","author":"Pilishvili","year":"2018"},{"issue":"11","key":"10.1016\/j.amepre.2019.10.022_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss6611a1","article-title":"Surveillance of vaccination coverage among adult populations - United States, 2015","volume":"66","author":"Williams","year":"2017","journal-title":"MMWR Surveill Summ"},{"issue":"3","key":"10.1016\/j.amepre.2019.10.022_bib0009","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/431521","article-title":"The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults","volume":"192","author":"Kyaw","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.amepre.2019.10.022_bib0010","unstructured":"CDC. CDC vaccine price list. www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccine-management\/price-list\/index.html. Updated September 1, 2019. Accessed September 25, 2019."},{"issue":"7","key":"10.1016\/j.amepre.2019.10.022_bib0011","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1007\/s11606-018-4471-1","article-title":"Racial and ethnic disparities in diagnosis of chronic medical conditions in the USA","volume":"33","author":"Kim","year":"2018","journal-title":"J Gen Intern Med"},{"issue":"10","key":"10.1016\/j.amepre.2019.10.022_bib0012","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.2105\/AJPH.2009.181313","article-title":"Socioeconomic and racial\/ethnic disparities in the incidence of bacteremic pneumonia among US adults","volume":"100","author":"Burton","year":"2010","journal-title":"Am J Public Health"},{"issue":"39","key":"10.1016\/j.amepre.2019.10.022_bib0013","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1016\/j.vaccine.2010.07.037","article-title":"Prevalence of high-risk indications for influenza vaccine varies by age, race, and income","volume":"28","author":"Zimmerman","year":"2010","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.amepre.2019.10.022_bib0014","first-page":"540","article-title":"Racial disparities in adult pneumococcal vaccination indications and pneumococcal hospitalizations in the U.S","volume":"111","author":"Nowalk","year":"2019","journal-title":"J Natl Med Assoc"},{"issue":"5","key":"10.1016\/j.amepre.2019.10.022_bib0015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/cid\/ciw808","article-title":"Socioeconomic factors explain racial disparities in invasive community-associated methicillin-resistant Staphylococcus aureus disease rates","volume":"64","author":"See","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.amepre.2019.10.022_bib0016","doi-asserted-by":"crossref","first-page":"e60273","DOI":"10.1371\/journal.pone.0060273","article-title":"Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques","volume":"8","author":"Said","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.amepre.2019.10.022_bib0017","article-title":"Physician fee schedule search. (CPT 90471)","year":"2017","journal-title":"Data Year"},{"issue":"1","key":"10.1016\/j.amepre.2019.10.022_bib0018","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/003335491012500107","article-title":"Estimates of state-level health-care expenditures associated with disability","volume":"125","author":"Anderson","year":"2010","journal-title":"Public Health Rep"},{"issue":"6","key":"10.1016\/j.amepre.2019.10.022_bib0019","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","article-title":"Toward consistency in cost-utility analyses: using national measures to create condition-specific values","volume":"36","author":"Gold","year":"1998","journal-title":"Med Care"},{"issue":"12","key":"10.1016\/j.amepre.2019.10.022_bib0020","doi-asserted-by":"crossref","first-page":"960","DOI":"10.7326\/0003-4819-138-12-200306170-00007","article-title":"Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race","volume":"138","author":"Sisk","year":"2003","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.amepre.2019.10.022_bib0021","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12879-017-2302-3","article-title":"The impact of community-acquired pneumonia on the health-related quality-of-life in elderly","volume":"17","author":"Mangen","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.amepre.2019.10.022_bib0022","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jama.281.3.243","article-title":"Safety of revaccination with pneumococcal polysaccharide vaccine","volume":"281","author":"Jackson","year":"1999","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.amepre.2019.10.022_bib0023","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.vaccine.2008.01.007","article-title":"Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis","volume":"26","author":"Smith","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.amepre.2019.10.022_bib0024","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/cid\/cis354","article-title":"Effectiveness and serotype coverage: key criteria for pneumococcal vaccines for adults","volume":"55","author":"Grabenstein","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.amepre.2019.10.022_bib0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/cid\/cis364","article-title":"Editorial commentary: should 13-valent protein-conjugate pneumococcal vaccine be used routinely in adults?","volume":"55","author":"Musher","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"23","key":"10.1016\/j.amepre.2019.10.022_bib0026","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1001\/jama.2016.16477","article-title":"Prevalence of immunosuppression among US adults, 2013","volume":"316","author":"Harpaz","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.amepre.2019.10.022_bib0027","unstructured":"HHS, CDC. Pneumococcal vaccine timing for adults. www.cdc.gov\/vaccines\/vpd\/pneumo\/downloads\/pneumo-vaccine-timing.pdf. Updated November 30, 2015. Accessed September 25, 2019."},{"issue":"3\u20134","key":"10.1016\/j.amepre.2019.10.022_bib0028","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0264-410X(02)00451-6","article-title":"Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly","volume":"21","author":"Fry","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2019.10.022_bib0029","series-title":"Economic analysis of sustaining the current recommendation for PCV13 use among adults 65 years of older in the context of continued indirect effects from the pediatric PCV13 program","author":"Stoecker","year":"2018"},{"key":"10.1016\/j.amepre.2019.10.022_bib0030","series-title":"Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae","year":"2017"},{"issue":"9","key":"10.1016\/j.amepre.2019.10.022_bib0031","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness \u2014 the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amepre.2019.10.022_bib0032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149540","article-title":"Cost-effectiveness of vaccinating immunocompetent \u226565 year olds with the 13-valent pneumococcal conjugate vaccine in England","volume":"11","author":"van Hoek","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.amepre.2019.10.022_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192640","article-title":"Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands","volume":"13","author":"Thorrington","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.amepre.2019.10.022_bib0034","unstructured":"Leidner AL. Overview of three economic analyses of pneumococcal vaccinations at age 65. Advisory Committee on Immunization Practices February 2019 meeting. www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2019-02\/Pneumococcal-4-Leidner-508.pdf. Updated April 14, 2019. Accessed November 5, 2019."},{"issue":"5","key":"10.1016\/j.amepre.2019.10.022_bib0035","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amepre.2019.10.022_bib0036","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"14","key":"10.1016\/j.amepre.2019.10.022_bib0037","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.vaccine.2019.01.002","article-title":"Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50\u201264 years compared to the US general population","volume":"37","author":"Wateska","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.amepre.2019.10.022_bib0038","unstructured":"Pilishvili T. 13-valent pneumococcal conjugate vaccine (PCV13) effects on disease caused by serotype 3. Advisory Committee on Immunization Practices February 2019 meeting. https:\/\/stacks.cdc.gov\/view\/cdc\/78091. Updated April 16, 2019. Accessed November 11, 2019."}],"container-title":["American Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379719305094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749379719305094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:53:46Z","timestamp":1760082826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749379719305094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0749379719305094"],"URL":"https:\/\/doi.org\/10.1016\/j.amepre.2019.10.022","relation":{},"ISSN":["0749-3797"],"issn-type":[{"value":"0749-3797","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumococcal Vaccination in Adults Aged \u226565 Years: Cost-Effectiveness and Health Impact in U.S. Populations","name":"articletitle","label":"Article Title"},{"value":"American Journal of Preventive Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amepre.2019.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}